DoorDash R&D decreased by 5.0% to $398.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 30.1%, from $306.00M to $398.00M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 35.1% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $100.00M | $115.00M | $133.00M | $148.00M | $205.00M | $226.00M | $250.00M | $231.00M | $269.00M | $250.00M | $253.00M | $279.00M | $303.00M | $289.00M | $297.00M | $306.00M | $351.00M | $355.00M | $419.00M | $398.00M |
| QoQ Change | — | +15.0% | +15.7% | +11.3% | +38.5% | +10.2% | +10.6% | -7.6% | +16.5% | -7.1% | +1.2% | +10.3% | +8.6% | -4.6% | +2.8% | +3.0% | +14.7% | +1.1% | +18.0% | -5.0% |
| YoY Change | — | — | — | — | +105.0% | +96.5% | +88.0% | +56.1% | +31.2% | +10.6% | +1.2% | +20.8% | +12.6% | +15.6% | +17.4% | +9.7% | +15.8% | +22.8% | +41.1% | +30.1% |